Clinical Trial Update: OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome [Phase 3]

View source ↗

Summary

ACADIA Pharmaceuticals is conducting an ongoing Phase 3 open-label extension study of carbetocin nasal spray to treat hyperphagia in Prader-Willi syndrome, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• Carbetocin nasal spray (carbetocin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Hyperphagia in Prader-Willi Syndrome | Phase 3 | Status: ENROLLING_BY_INVITATION